PTC Therapeutics Executive Compensation Revealed
Ticker: PTCT · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1070081
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: PTCT
TL;DR
PTCT proxy shows exec comp details for 2024, including equity awards for Klein & Peltz.
AI Summary
PTC Therapeutics, Inc. filed its DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its Principal Executive Officer (PEO) and Non-PEO NEOs, with specific values for year-end outstanding and unvested awards, as well as adjustments to equity awards. Matthew Klein and Stuart Peltz are listed as members, with compensation data spanning from 2020 to 2024.
Why It Matters
This filing provides transparency into how PTC Therapeutics compensates its top executives, which can influence investor perception and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can sometimes signal changes in company leadership or financial strategy, which may carry inherent risks.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation details.)
- 2020-2024 — Compensation Data Range (Historical executive compensation information provided.)
Key Players & Entities
- PTC Therapeutics, Inc. (company) — Filer
- Matthew Klein (person) — Executive Member
- Stuart Peltz (person) — Executive Member
- 0001070081 (company) — Central Index Key
FAQ
What was the total value of equity awards granted to the Principal Executive Officer (PEO) in 2024?
The filing indicates data for 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' and 'EqtyAwrdsAdjsMember' for PEOs, but specific dollar amounts for 2024 grants are not detailed in the provided snippet.
Who are the named executive officers (NEOs) mentioned in this filing?
Matthew Klein and Stuart Peltz are identified as members, likely representing NEOs, with compensation data provided for them.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is a definitive proxy statement used to solicit shareholder votes on important corporate matters, including the election of directors and executive compensation.
When is the fiscal year end for PTC Therapeutics?
The fiscal year end for PTC Therapeutics is December 31st.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for PTC Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 by Matthew Klein regarding PTC THERAPEUTICS, INC. (PTCT).